Trial Profile

A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2024 Results of a secondary analysis changes in muscle quality, quantity, and function among people with HIV treated with semaglutide using data from this study presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
05 Mar 2024 According to ACTG media release, Todays oral session detailing results from this trial was presented by SLIM LIVER Protocol Co-Chair Jordan E. Lake, M.D., M.Sc., UTHealth Houston and yesterdays poster session was presented by Grace L. Ditzenberger, P.T., D.P.T., University of Colorado - Anschutz Medical Campus.
05 Mar 2024 Results published in the ACTG Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com